On February 27, 2017 NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, reported a novel approach to profiling immuno-oncology protein targets through digital quantification using the nCounter Analysis System (Press release, NanoString Technologies, FEB 27, 2017, View Source [SID1234517891]). The data was presented by David Lee, M.D., Ph.D., a Senior Investigator, with the Novartis Institutes for BioMedical Research as part of a Technology Access Program (TAP) for NanoString’s Digital Spatial Profiling (DSP) technology, and was the focus of a poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) – Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (ASCO-SITC) joint conference, being held Orlando, Florida. Schedule your 30 min Free 1stOncology Demo! "Our DSP platform enabled the assessment of 30 proteins simultaneously with digital spatial context that demonstrated strong correlation with IHC methods," stated Joe Beechem, Ph.D., senior vice president of R&D for NanoString. "We were able to characterize the tumor microenvironment allowing us to better understand the function of the immune system and the status of T-cells and checkpoint markers that are critical in immuno-oncology."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through the collaboration with Novartis, researchers demonstrated:
Spatially-resolved, quantitative protein profiling in FFPE tissue enables detailed molecular characterization of tonsil, melanoma and colorectal tumors
A prototype instrument enabled 30+ multiplexed protein characterization from regions of interest 650 micron down to single cell resolution
The strong correlation of NanoString DSP data to Novartis IHC data indicates the feasibility to spatially profile multiple key proteins with no destruction of patient tissue
Future advances may enable characterization of up to 800 RNA and protein targets at high resolution within spatial context from the complex tumor microenvironment
NanoString is expanding access to the Digital Spatial Profiling TAP. Under the program, technology access partners can submit up to 20 FFPE tissue sections and NanoString will perform a high-plex protein spatial profiling assay from a panel of 30 pre-validated antibodies. An assay report along with raw digital data and processed results will be provided back to partners. Researchers interested in participating in NanoString’s technology access program for its Digital Spatial Profiling technology should contact the company at [email protected].
Digital Spatial Profiling poster:
"A new approach for immuno-oncology biomarker discovery: High-plex, spatial protein profiling based on NanoString digital quantification. (Abstract 27 / BOARD C10)"
First Author: David Lee, M.D., Ph.D., Senior Investigator, Novartis Institutes for BioMedical Research
Poster Session B: Biomarkers and Inflammatory Signatures, and Modulating Innate Immunity
Date: Friday, February 24: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM